GlassScriptPhysician profile
Alex Sherman
NPI 1578587283
$55,047.74
in general payments reported to CMS, 2019-2025
48 companies · $3,286 in 2025
The $3,286 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $3,621 · 2021: $6,731 · 2022: $3,993 · 2023: $4,052 · 2024: $23K · 2025: $3,286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Food and Beverage: $8,402 · Travel and Lodging: $2,308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,800.00 |
| Food and Beverage | $8,402.18 |
| Travel and Lodging | $2,307.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $23,615.20 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11,263.31 | 2019-2024 | Plenvu, Xifaxan, Trulance |
| Redhill Biopharma INC. | $5,020.99 | 2020-2024 | Talicia, Aemcolo, Movantik |
| Abbvie INC. | $4,553.68 | 2019-2025 | Skyrizi, Rinvoq, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,343.81 | 2019-2024 | Entyvio |
| Qol Medical, LLC | $1,280.73 | 2019-2024 | Sucraid, Sucraid |
| Pfizer INC. | $1,273.48 | 2019-2025 | |
| Janssen Biotech, INC. | $721.41 | 2019-2024 | Stelara |
| Merck Sharp & Dohme LLC | $684.63 | 2019-2024 | Dificid |
| Celgene Corporation | $609.32 | 2019-2024 | Zeposia |
| Ferring Pharmaceuticals INC. | $570.00 | 2020-2025 | Rebyota, Clenpiq |
| Napo Pharmaceuticals INC | $550.11 | 2021-2025 | Mytesi |
| E.R. Squibb & Sons, L.L.C. | $500.65 | 2021-2023 | Zeposia |
| Genzyme Corporation | $442.07 | 2022-2024 | |
| Janssen Research & Development, LLC | $309.72 | 2022 |
Show all 46 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Sherman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.